Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Wilate prophylaxis in Von Willebrand disease
2018-004675-13Phase 3Completed
- Sponsor
- Octapharma
- Start
- Feb 2019
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of von Willebrand factor concentrate in Type 3 von Willebrand disease, von Willebrand disease (VWD) and Type 1 von Willebrand disease, sponsored by Octapharma. Primary endpoint: Total annualized bleeding rate reduction. Started Feb 2019; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
Type 3 von Willebrand diseasevon Willebrand disease (VWD)Type 1 von Willebrand disease
Beyond the preview
Go deeper on 2018-004675-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004675-13.